Q&A Exclusive: Ampio's Leadership Aggressively Focused on Significant Licensing Opportunities and Getting Trials Completed

(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 09/14/11 -- The low-float shares of Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) have continued their steady uptrend despite these volatile markets. Much of that appreciation may be due to the investment community's growing awareness of the small firm's impressive pipeline and strategy.

A new report featuring an exclusive interview with Michael Macaluso, the Founder and Chairman of Ampio Pharmaceuticals explores the firm focus on our significant licensing opportunities and push ahead to get clinical trials completed. That report may be read at:



In addition, investors may access BioMedReports' for use as a tool in more profitable trading by visiting:



News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com





Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 14.09.2011 - 12:08 Uhr
Sprache: Deutsch
News-ID 65773
Anzahl Zeichen: 0

contact information:
Town:

LOS ANGELES, CA

Kategorie:

Investment Opinion

Diese Pressemitteilung wurde bisher 280 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Q&A Exclusive: Ampio's Leadership Aggressively Focused on Significant Licensing Opportunities and Getting Trials Completed"
steht unter der journalistisch-redaktionellen Verantwortung von

BioMedReports (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead ...

LOS ANGELES, CA -- (Marketwired) -- 11/06/13 -- In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed bioph ...

Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" ...

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- With shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (NYSE MKT: CVM) who last provide ...

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D. ...

LOS ANGELES, CA -- (Marketwired) -- 07/23/13 -- It has been over a year since Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talk ...

Alle Meldungen von BioMedReports